Pasar al contenido principal

EVOLUCION TUMORAL: DECODIFICANDO LA DESDIFERENCIACION DE LAS CELULAS CANCEROSAS

PID2024-155394OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para la Investigación y el Desarrollo Experimental
Subprograma Subprograma Estatal de Generación de Conocimiento Científico-Técnico y Desarrollo Experimental
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2024
Plan Estatal 2024-2027 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tfcp2l1 as a central integrator of hypoxia, dedifferentiation, and tumor progression

  • Clemente-González, Cynthia
  • Carnero, Amancio
The gene Tfcp2l1 has emerged as a central player linking key processes in cancer biology: hypoxia, immortalization, dedifferentiation, and tumor progression. Originally identified for its role in maintaining pluripotency in embryonic stem cells, Tfcp2l1 has been found to reappear in various cancers, especially under conditions of low oxygen (hypoxia). Hypoxia, a common feature of solid tumors, triggers the reactivation of developmental genes like Tfcp2l1, enabling cancer cells to dedifferentiate and adopt stem cell-like properties. This dedifferentiation facilitates the immortalization of cells—allowing them to bypass senescence and continue proliferating. Tfcp2l1 contributes to this process by regulating transcriptional networks that suppress differentiation and support self-renewal. Its expression correlates with poor prognosis in several cancers, highlighting its potential role in tumor aggressiveness and resistance to therapy. By acting at the intersection of cellular plasticity, stress adaptation, and oncogenic transformation, Tfcp2l1 may serve as a molecular bridge linking early developmental programs with malignant behaviors. Understanding how Tfcp2l1 integrates signals from hypoxic stress and drives dedifferentiation could uncover new therapeutic targets aimed at reversing or halting tumor progression., This work was supported by grants from the Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I+D+I, Agencia Estatal deInvestigación (AEI) and Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER,UE): PID2021-122629OB-I00, PID2024-155394OB-I00 and RED2024-153635-T (iDIFFER network) grants from AEI-MICIU/ 10.13039/501100011033 and, by “ERDF A way of making Europe”, by the “European Union” or by the “European Union Next Generation EU/PRTR” from CIBER de Cáncer(CB16/12/00275), co-funded by FEDER from Regional Development European Funds (European Union); from Consejería de Salud and from Consejería de Economía, Conocimiento, Empresas y Universidad de la Junta de Andalucía (DGP_PIDI_2024_00907). Special thanks to the AECC Foundation (Spanish Association of Cancer Research) for supporting this work (founding ref. GC16173720CARR)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Role of Microbiota in Ovarian Cancer: Implications for Treatment Response and Therapeutic Strategies

  • Blanco, José Ramón
  • Campo, Rosa del
  • Avendaño-Ortiz, José
  • Laguna-Olmos, Mariano
  • Carnero, Amancio
first_pagesettingsOrder Article Reprints Open AccessFeature PaperReview The Role of Microbiota in Ovarian Cancer: Implications for Treatment Response and Therapeutic Strategies by Jose-Ramon Blanco 1,2,3,*ORCID,Rosa del Campo 4,5,*ORCID,José Avendaño-Ortiz 4,6ORCID,Mariano Laguna-Olmos 1ORCID andAmancio Carnero 7,8ORCID 1 Hospital Universitario San Pedro, 26006 Logroño, Spain 2 Centro de Investigación Biomédica de La Rioja (CIBIR), 26006 Logroño, Spain 3 Grupo de Investigación en Cuidados y Salud (GRUPAC), de la Universidad de La Rioja, 26006 Logroño, Spain 4 Centro de Investigación Biomédica en Red Enfermedades Infecciosas (CIBERINFEC), 28029 Madrid, Spain 5 Facultad Ciencias de la Salud, Universidad de La Rioja, La Rioja, 26006 Logroño, Spain 6 Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain 7 Instituto de Biomedicina de Sevilla (IBIS)/HUVR/CSIC, Universidad de Sevilla, 41013 Sevilla, Spain 8 CIBER de Cancer (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain * Authors to whom correspondence should be addressed. Cells 2025, 14(22), 1813; https://doi.org/10.3390/cells14221813 Submission received: 30 September 2025 / Revised: 13 November 2025 / Accepted: 14 November 2025 / Published: 19 November 2025 Downloadkeyboard_arrow_down Browse Figures Versions Notes Abstract Cancer remains a global health challenge (18.1 million new cases in 2020), with incidence projected to reach 28 million within two decades. Ovarian cancer (OC) is the deadliest gynecologic malignancy, usually diagnosed at advanced stages and with poorly understood etiology. Emerging evidence implicates reproductive tract and gut microbiota in OC biology. Microbiota shape carcinogenesis via turnover, immunity, and metabolism; dysbiosis promotes DNA damage, inflammation, and carcinogenic metabolites, engaging multiple hallmarks of cancer. In OC, microbes may reach tumors by local ascent, translocation, or hematogenous spread, originating from vagina, upper reproductive tract, peritoneal fluid, or gut. Lactobacillus-dominant vaginal communities support mucosal integrity, whereas anaerobes disrupt barriers, increase inflammation, and correlate with OC risk; mouse models show vaginal dysbiosis accelerates tumor progression. Distinct microbial profiles in upper reproductive sites and peritoneal fluid associated with immune remodeling. Gut dysbiosis drives barrier loss, immune imbalance, and estrogen reactivation. Microbial metabolites (lipopolysaccharides, short-chain fatty acids) modulate oncogenic pathways, altering epithelial–mesenchymal transition, immune evasion, and drug resistance. Across cohorts, OC tissues and fluids show Pseudomonadota/Bacteroidota enrichment and Akkermansia depletion; fecal microbiota from OC patients accelerates tumor growth in mice, whereas Akkermansia supplementation restores antitumor immunity. Antibiotic exposure and platinum resistance associate with reduced diversity and expansion of lactate-producing taxa. Microbiome-informed interventions–diet, probiotics/postbiotics, fecal microbiota transfer, and selective antibiotics–may augment chemotherapy and immunotherapy. Overall, the microbiome is a modifiable determinant of OC risk, progression, and treatment response, warranting rigorous, standardized, multi-omics studies., This work has been financed by MCIU/AEI/FEDER, UE: PID2024-155394OB-I00; CIBER de Cáncer (CB16/12/00275), and DGP_PIDI_2024_00907, from the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities from Junta de Andalucia; and co-financed by the ISCIII-Dirección General Adjunta de Evaluación y Promoción de la Investigación—Fondo Europeo de Desarrollo Regional “A Way of Making Europe”, Instituto de Salud Carlos III FEDER, together with a grant from the Instituto de Salud Carlos III (MePRAM Project, PMP22/00092), Ministerio de Ciencia e Innovación, financed by NextGeneration European Union funds within the framework of the Resilience and Recovery Fund., Peer reviewed